Vabysmo (Faricimab) | EyeKnow O.D.

Approved uses

Neovascular (wet) age-related macular degeneration and diabetic macular edema

6 mg (0.05 mL of 120 mg/mL) intravitreally every 4 weeks for the first 4 doses, then extended on OCT and acuity response up to every 16 weeks

Dual VEGF-A and angiopoietin-2 inhibition, which is what allows the extended interval

Macular edema following retinal vein occlusion

6 mg (0.05 mL of 120 mg/mL) intravitreally every 4 weeks

Contraindications

Ocular or periocular infection Active intraocular inflammation Hypersensitivity.

Available Forms

Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL) in a single-dose prefilled syringe or single-dose vial.

Mechanism of Action

Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD, DME, and RVO. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD, DME, and RVO has yet to be established.